Intriguingly, SPH treatment prevented a significant increase in pro-inflammatory TNF-α and IL-6 and additionally augmented the production of anti-inflammatory IL-10 and TGF-β1 compared with the other two colitis groups (p < 0.01). This evidence concerns the gene IL10 and colitis.